{"classes":["LITERATURE REFERENCE","PRIMARYSOURCECOUNTRY","REPORTERORGANIZATION","REPORTERCOUNTRY","PATIENTONSETAGE","PATIENTSEX","RESULTSTESTSPROCEDURES","PATIENTDRUGNAME","PATIENTDRUGINDICATION","PATIENTDRUGREACTION","PRIMARYSOURCEREACTION","MEDICINALPRODUCT","REPORTERDEPARTMENT","PATIENTDEATHREPORT","REACTIONSTARTDATE","PATIENTAGEGROUP","SERIOUSNESSOTHER","SERIOUSNESSHOSPITALIZATION","REPORTERGIVENAME","REPORTERFAMILYNAME","REPORTERSTREET","REPORTERCITY","REPORTERPOSTCODE","TESTNAME","TESTRESULT","DRUGDOSAGEFORM","DRUGADMINISTRATIONROUTE","DRUGINDICATION","DRUGSTARTPERIODUNIT","SERIOUSNESSLIFETHREATENING","TESTUNIT","MEDICALHISTORYEPISODE","PATIENTPASTDRUGTHERAPY","DRUGSTRUCTUREDOSAGEUNIT","REPORTERMIDDLENAME","REPORTERSTATE","SERIOUSNESSDEATH","ACTIONDRUG","DRUGDOSAGETEXT","DRUGSTRUCTUREDOSAGENUMB","PATIENTWEIGHT","SUSPECTPRODUCT","CONCOMITANTPRODUCT","PATIENTHEIGHT","DRUGINTERVALDOSAGEDEFINITION","INTERACTINGPRODUCT"],"annotations":[["Govindapala et al. Journal of Medical Case Reports (2022) 16:327 Page 6 of 6\r\n•\r\nfast, convenient online submission\r\n•\r\nthorough peer review by experienced researchers in your field\r\n•\r\nrapid publication on acceptance\r\n•\r\nsupport for research data, including large and complex data types\r\n•\r\ngold Open Access which fosters wider collaboration and increased citations\r\n• maximum visibility for your research: over 100M website views per year\r\nAt BMC, research is always in progress.Sri Lanka \r\nLearn more biomedcentral.com/submissions\r\nReady to submit your research ? Choose BMC and benefit from:\r\nof anaphylaxis associated with high blood pressure and\r\northostatic intolerance.\r\nAbbreviations\r\nBP: Blood pressure; CRP: C-reactive protein; ED: Emergency department; FBC:\r\nFull blood count; ICU: Intensive care unit; IM: Intramuscular; NSAIDs: Nonsteroidal\r\nanti-inflammatory drugs; SR: Slow release.\r\nAcknowledgements\r\nThe authors would like to acknowledge the ICU team who provided care for\r\nthis patient during the ICU stay.\r\nAuthor contributions\r\nDG and CU were involved in the initial management and follow-up of the\r\npatient. DG, DW, and USS wrote the initial manuscript. DG, CU, and DN\r\nedited the manuscript. All authors read and approved the final draft of the\r\nmanuscript.\r\nFunding\r\nThe authors did not receive funding for the specific case report, and patient\r\ncare was provided as a part of employment.\r\nAvailability of data and materials\r\nThe supporting data and material of this case report are not publicly available\r\nowing to risk of breach of patient confidentiality but are available from the\r\ncorresponding author on reasonable request. The patient’s de-identification\r\nwill be maintained in sharing the data.\r\nDeclarations\r\nEthics approval and consent to participate\r\nNot applicable.\r\nConsent for publication\r\nWritten informed consent was obtained from the patient for publication of\r\nthis case report and any accompanying images. A copy of the written consent\r\nis available for review by the Editor-in-Chief of this journal.\r\nCompeting interests\r\nThe authors declare that they have no competing interests.\r\nAuthor details\r\n1 Department of Clinical Sciences, Faculty of Medicine, General Sir John Kotelawala\r\nDefence University, Ratmalana, Sri Lanka. 2 Department of Paraclinical\r\nSciences, Faculty of Medicine, General Sir John Kotelawala Defence University,\r\nRatmalana, Sri Lanka. 3 Department of Physiology, Faculty of Medical Sciences,\r\nUniversity of Sri Jayewardenepura, Gangodawila, Nugegoda, Sri Lanka.\r\nReceived: 13 January 2022 Accepted: 16 July 2022\r\nReferences\r\n1. Muraro A, Roberts G, Worm M, Bilò MB, Brockow K, Fernández Rivas M,\r\net al. Anaphylaxis: guidelines from the European Academy of Allergy and\r\nClinical Immunology. Allergy. 2014;69(8):1026–45. https:// doi. org/ 10.\r\n1111/ all. 12437.\r\n2. Simons FER, Ardusso LRF, Bilò MB, El-Gamal YM, Ledford DK, Ring J, et al.\r\nWorld Allergy Organization guidelines for the assessment and management\r\nof anaphylaxis. World Allergy Organ J. 2011;4(2):13–37.\r\n3. Kemp SF, Lockey RF, Simons FER. World Allergy Organization ad hoc Committee\r\non Epinephrine in Anaphylaxis. Epinephrine: the drug of choice\r\nfor anaphylaxis—a statement of the world allergy organization. World\r\nAllergy Organ J. 2008;1(7 Suppl):S18-26.\r\n4. Solmazgul E, Kutlu A, Dogru S, Ozalper V, Cetindagli I, Sezer O, et al.\r\nAnaphylactic reactions presenting with hypertension. SpringerPlus.\r\n2016;5(1):1223.\r\n5. Simons FER. Anaphylaxis. J Allergy Clin Immunol. 2010;125(2 Suppl\r\n2):S161–81.\r\n6. Reber LL, Hernandez JD, Galli SJ. The pathophysiology of anaphylaxis. J\r\nAllergy Clin Immunol. 2017;140(2):335–48.\r\n7. McD Fisher M. Clinical observations on the pathophysiology and treatment\r\nof anaphylactic cardiovascular collapse. Anaesth Intensive Care.\r\n1986. https:// doi. org/ 10. 1177/ 03100 57X86 01400 105.\r\n8. van der Linden PW, Struyvenberg A, Kraaijenhagen RJ, Hack CE, van der\r\nZwan JK. Anaphylactic shock after insect-sting challenge in 138 persons\r\nwith a previous insect-sting reaction. Ann Intern Med. 1993;118(3):161–8.\r\n9. Li M, Liu K, Michalicek J, Angus JA, Hunt JE, Dell’Italia LJ, et al. Involvement\r\nof chymase-mediated angiotensin II generation in blood pressure regulation.\r\nJ Clin Invest. 2004;114(1):112–20.\r\n10. Pumphrey RSH. Fatal posture in anaphylactic shock. J Allergy Clin Immunol.\r\n2003;112(2):451–2.\r\n11. Ko BS, Kim JY, Seo D-W, Kim WY, Lee JH, Sheikh A, et al. Should adrenaline\r\nbe used in patients with hemodynamically stable anaphylaxis? Incident\r\ncase control study nested within a retrospective cohort study. Sci Rep.\r\n2016;6:20168.\r\n12. Anaphylaxis and hypertension. Ask The Expert. 2017. Available from:\r\nhttps:// www. aaaai. org/ aller gist- resou rces/ ask- the- expert/ answe rs/ oldask-\r\nthe- exper ts/ hyper tensi on- anaph ylaxis.\r\n13. Pumphrey. Lessons for management of anaphylaxis from a study of fatal\r\nreactions. Clin Exp Allergy. 2000;30(8):1144–50. https:// doi. org/ 10. 1046/j.\r\n1365- 2222. 2000. 00864.x.\r\n14. Liyanage CK, Galappatthy P, Seneviratne SL. Corticosteroids in management\r\nof anaphylaxis; a systematic review of evidence. Eur Ann Allergy\r\nClin Immunol. 2017;49(05):196.\r\n15. Campbell DE. Anaphylaxis management: time to re-evaluate the role of\r\ncorticosteroids. J Allergy Clin Immunol Pract. 2019;7(7):2239–40.\r\n16. Cardona V, Ansotegui IJ, Ebisawa M, El-Gamal Y, Fernandez Rivas M,\r\nFineman S, et al. World Allergy Organization anaphylaxis guidance 2020.\r\nWorld Allergy Organ J. 2020;13(10):100472.\r\nPublisher’s Note\r\nSpringer Nature remains neutral with regard to jurisdictional claims in published\r\nmaps and institutional affiliations.\r\n\r\nGovindapala D, Senarath US, Wijewardena D, Nakkawita D, Undugodage C. An unusual presentation of anaphylaxis with severe hypertension: a case report. Journal of medical case reports. 2022;16(1):327. DOI: 10.1186/s13256-022-03528-y\r\n\r\nA case received from Sri Lanka with suspect DICLOFENAC SODIUM 100 mg\r\n\r\n",{"entities":[[2158,2175,"REPORTERDEPARTMENT"],[2247,2256,"REPORTERCITY"],[2258,2268,"REPORTERCOUNTRY"],[2330,2376,"REPORTERORGANIZATION"],[3369,3421,"PRIMARYSOURCEREACTION"],[4637,4650,"PRIMARYSOURCEREACTION"],[5655,5666,"REPORTERFAMILYNAME"],[5667,5668,"REPORTERGIVENAME"],[5670,5885,"LITERATURE REFERENCE"],[5910,5919,"PRIMARYSOURCECOUNTRY"],[5933,5950,"SUSPECTPRODUCT"],[5951,5954,"DRUGSTRUCTUREDOSAGEUNIT"],[5955,5957,"DRUGSTRUCTUREDOSAGENUMB"]]}],["Govindapala et al. Journal of Medical Case Reports (2022) 16:327 Page 6 of 6\r\n•\r\nfast, convenient online submission\r\n•\r\nthorough peer review by experienced researchers in your field\r\n•\r\nrapid publication on acceptance\r\n•\r\nsupport for research data, including large and complex data types\r\n•\r\ngold Open Access which fosters wider collaboration and increased citations\r\n• maximum visibility for your research: over 100M website views per year\r\nAt BMC, research is always in progress.Sri Lanka \r\nLearn more biomedcentral.com/submissions\r\nReady to submit your research ? Choose BMC and benefit from:\r\nof anaphylaxis associated with high blood pressure and\r\northostatic intolerance.\r\nAbbreviations\r\nBP: Blood pressure; CRP: C-reactive protein; ED: Emergency department; FBC:\r\nFull blood count; ICU: Intensive care unit; IM: Intramuscular; NSAIDs: Nonsteroidal\r\nanti-inflammatory drugs; SR: Slow release.\r\nAcknowledgements\r\nThe authors would like to acknowledge the ICU team who provided care for\r\nthis patient during the ICU stay.\r\nAuthor contributions\r\nDG and CU were involved in the initial management and follow-up of the\r\npatient. DG, DW, and USS wrote the initial manuscript. DG, CU, and DN\r\nedited the manuscript. All authors read and approved the final draft of the\r\nmanuscript.\r\nFunding\r\nThe authors did not receive funding for the specific case report, and patient\r\ncare was provided as a part of employment.\r\nAvailability of data and materials\r\nThe supporting data and material of this case report are not publicly available\r\nowing to risk of breach of patient confidentiality but are available from the\r\ncorresponding author on reasonable request. The patient’s de-identification\r\nwill be maintained in sharing the data.\r\nDeclarations\r\nEthics approval and consent to participate\r\nNot applicable.\r\nConsent for publication\r\nWritten informed consent was obtained from the patient for publication of\r\nthis case report and any accompanying images. A copy of the written consent\r\nis available for review by the Editor-in-Chief of this journal.\r\nCompeting interests\r\nThe authors declare that they have no competing interests.\r\nAuthor details\r\n1 Department of Clinical Sciences, Faculty of Medicine, General Sir John Kotelawala\r\nDefence University, Ratmalana, Sri Lanka. 2 Department of Paraclinical\r\nSciences, Faculty of Medicine, General Sir John Kotelawala Defence University,\r\nRatmalana, Sri Lanka. 3 Department of Physiology, Faculty of Medical Sciences,\r\nUniversity of Sri Jayewardenepura, Gangodawila, Nugegoda, Sri Lanka.\r\nReceived: 13 January 2022 Accepted: 16 July 2022\r\nReferences\r\n1. Muraro A, Roberts G, Worm M, Bilò MB, Brockow K, Fernández Rivas M,\r\net al. Anaphylaxis: guidelines from the European Academy of Allergy and\r\nClinical Immunology. Allergy. 2014;69(8):1026–45. https:// doi. org/ 10.\r\n1111/ all. 12437.\r\n2. Simons FER, Ardusso LRF, Bilò MB, El-Gamal YM, Ledford DK, Ring J, et al.\r\nWorld Allergy Organization guidelines for the assessment and management\r\nof anaphylaxis. World Allergy Organ J. 2011;4(2):13–37.\r\n3. Kemp SF, Lockey RF, Simons FER. World Allergy Organization ad hoc Committee\r\non Epinephrine in Anaphylaxis. Epinephrine: the drug of choice\r\nfor anaphylaxis—a statement of the world allergy organization. World\r\nAllergy Organ J. 2008;1(7 Suppl):S18-26.\r\n4. Solmazgul E, Kutlu A, Dogru S, Ozalper V, Cetindagli I, Sezer O, et al.\r\nAnaphylactic reactions presenting with hypertension. SpringerPlus.\r\n2016;5(1):1223.\r\n5. Simons FER. Anaphylaxis. J Allergy Clin Immunol. 2010;125(2 Suppl\r\n2):S161–81.\r\n6. Reber LL, Hernandez JD, Galli SJ. The pathophysiology of anaphylaxis. J\r\nAllergy Clin Immunol. 2017;140(2):335–48.\r\n7. McD Fisher M. Clinical observations on the pathophysiology and treatment\r\nof anaphylactic cardiovascular collapse. Anaesth Intensive Care.\r\n1986. https:// doi. org/ 10. 1177/ 03100 57X86 01400 105.\r\n8. van der Linden PW, Struyvenberg A, Kraaijenhagen RJ, Hack CE, van der\r\nZwan JK. Anaphylactic shock after insect-sting challenge in 138 persons\r\nwith a previous insect-sting reaction. Ann Intern Med. 1993;118(3):161–8.\r\n9. Li M, Liu K, Michalicek J, Angus JA, Hunt JE, Dell’Italia LJ, et al. Involvement\r\nof chymase-mediated angiotensin II generation in blood pressure regulation.\r\nJ Clin Invest. 2004;114(1):112–20.\r\n10. Pumphrey RSH. Fatal posture in anaphylactic shock. J Allergy Clin Immunol.\r\n2003;112(2):451–2.\r\n11. Ko BS, Kim JY, Seo D-W, Kim WY, Lee JH, Sheikh A, et al. Should adrenaline\r\nbe used in patients with hemodynamically stable anaphylaxis? Incident\r\ncase control study nested within a retrospective cohort study. Sci Rep.\r\n2016;6:20168.\r\n12. Anaphylaxis and hypertension. Ask The Expert. 2017. Available from:\r\nhttps:// www. aaaai. org/ aller gist- resou rces/ ask- the- expert/ answe rs/ oldask-\r\nthe- exper ts/ hyper tensi on- anaph ylaxis.\r\n13. Pumphrey. Lessons for management of anaphylaxis from a study of fatal\r\nreactions. Clin Exp Allergy. 2000;30(8):1144–50. https:// doi. org/ 10. 1046/j.\r\n1365- 2222. 2000. 00864.x.\r\n14. Liyanage CK, Galappatthy P, Seneviratne SL. Corticosteroids in management\r\nof anaphylaxis; a systematic review of evidence. Eur Ann Allergy\r\nClin Immunol. 2017;49(05):196.\r\n15. Campbell DE. Anaphylaxis management: time to re-evaluate the role of\r\ncorticosteroids. J Allergy Clin Immunol Pract. 2019;7(7):2239–40.\r\n16. Cardona V, Ansotegui IJ, Ebisawa M, El-Gamal Y, Fernandez Rivas M,\r\nFineman S, et al. World Allergy Organization anaphylaxis guidance 2020.\r\nWorld Allergy Organ J. 2020;13(10):100472.\r\nPublisher’s Note\r\nSpringer Nature remains neutral with regard to jurisdictional claims in published\r\nmaps and institutional affiliations.\r\n\r\nGovindapala D, Senarath US, Wijewardena D, Nakkawita D, Undugodage C. An unusual presentation of anaphylaxis with severe hypertension: a case report. Journal of medical case reports. 2022;16(1):327. DOI: 10.1186/s13256-022-03528-y\r\n\r\nA case received from Sri Lanka with suspect DICLOFENAC SODIUM 100 mg\r\n\r\n",{"entities":[[2158,2175,"REPORTERDEPARTMENT"],[2247,2256,"REPORTERCITY"],[2258,2268,"REPORTERCOUNTRY"],[2330,2376,"REPORTERORGANIZATION"],[3369,3421,"PRIMARYSOURCEREACTION"],[4637,4650,"PRIMARYSOURCEREACTION"],[5655,5666,"REPORTERFAMILYNAME"],[5667,5668,"REPORTERGIVENAME"],[5670,5885,"LITERATURE REFERENCE"],[5910,5919,"PRIMARYSOURCECOUNTRY"],[5933,5950,"SUSPECTPRODUCT"],[5951,5954,"DRUGSTRUCTUREDOSAGEUNIT"],[5955,5957,"DRUGSTRUCTUREDOSAGENUMB"]]}]]}